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Abstract 
Background: With the continuing development of new anti‑cancer drugs comes a need for preclinical experimental 
models capable of predicting the clinical activity of these novel agents in cancer patients. However existing models 
have a limited ability to recapitulate the clinical characteristics and associated drug sensitivity of tumors. Among the 
more promising approaches for improving preclinical models is direct implantation of patient‑derived tumor tissue 
into immunocompromised mice, such as athymic nude or non‑obese diabetic/severe combined immunodeficient 
(NOD/SCID) mice. In the current study, we attempted to develop patient‑derived xenograft (PDX) models using tissue 
fragments from surgical samples of brain tumors.
Methods: In this approach, tiny tissue fragments of tumors were biopsied from eight brain tumor patients—seven 
glioblastoma patients and one primitive neuroectodermal tumor patient. Two administration methods—a cut‑down 
syringe and a pipette—were used to implant tissue fragments from each patient into the brains of athymic nude 
mice.
Results: In contrast to previous reports, and contrary to our expectations, we found that none of these fragments 
from brain tumor biopsies resulted in the successful establishment of xenograft tumors.
Conclusions: These results suggest that fragments of surgical specimens from brain tumor patients are unsuitable 
for implementation of brain tumor PDX models, and instead recommend other in vivo testing platforms for brain 
tumors, such as cell‑based brain tumor models.
Keywords: Glioblastoma, Model failure, Patient‑derived xenograft, Primitive neuro‑ectodermal tumor, Tissue 
fragment
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Background
The multiple genetic lesions and complex signaling 
cascades associated with the etiology and progres-
sion of cancer contribute to difficulties in understand-
ing the biology of this disease [1]. Of the various kinds 
of cancers, brain tumors, especially glioblastoma (GBM), 
are among the most lethal [2]. Thus not surprisingly, con-
siderable research effort has been devoted to increasing 
the efficacy of new treatments for GBM [3–6]. Although 
these efforts have been ongoing for decades, preclinical 
tumor models suitable for evaluating the effects of anti-
cancer therapies are lacking [7–9].
A number of animal models of primary brain tumors 
have been developed to understand brain tumors, includ-
ing chemically induced models, genetically engineered 
mouse models, and tumor xenograft models [8]. Among 
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these animal models, tumor xenografts derived from 
human GBM cell lines have traditionally been used as a 
preclinical tool to understand cancer biology and thera-
peutic efficacy. However, GBM cell line xenografts have 
a number of shortcomings for preclinical use, includ-
ing (i) the failure of tumor xenografts to mirror patient 
responses [10, 11] because they do not accurately reflect 
the clinical characteristics of the patient tumor, (ii) differ-
ences in pharmacokinetics between animal models and 
as humans [12], and (iii) the loss of biological proper-
ties of cancer cell lines during the process of establishing 
them [13, 14].
To overcome the shortcomings of previous tumor 
models and to preserve the oncological heterogene-
ity observed in patients, researchers are continuing to 
focus on new animal testing platforms for cancer. Sev-
eral recent studies have reported innovative preclinical 
animal models generated by transplanting sectioned 
patient-derived tumor tissue fragments, rather than cell 
lines, into immunocompromised mice, such as athymic 
nude or non-obese diabetic/severe combined immu-
nodeficient (NOD/SCID) mice [7, 15–18], a concept 
generally referred to in the literature as patient-derived 
xenograft (PDX) [15, 18]. Maintaining the histologi-
cal characteristics and primary architecture of tumors 
is one of the major advantages of the PDX model [18, 
19]. In addition, the propagation of tumors in successive 
generations of mouse hosts enables PDX cells to avoid 
the stressful conditions that possibly occur during cell 
culture [20]. These advantages make PDXs biologically 
stable and enable them to maintain the molecular char-
acteristics of the primary tumors from which they were 
derived [20, 21]. Because of these strengths, PDXs are 
useful not only for the preclinical testing of drugs, but 
also to verify molecular changes and signaling pathways 
in oncology [1].
A recent series of studies in the brain tumor field has 
made meaningful progress in animal testing platforms 
using patient-derived tumorspheres [10, 22–24] and 
enzymatically dissociated cells [25]. However, because 
these previous studies used tumor cells, the resulting 
animal models may not satisfy the classic definition of a 
PDX [1, 15, 16, 18]. Making PDXs more similar to the 
originating GBM patient tumors may instead require 
injection of patient-derived tumor tissue fragments. In 
this context, one report concluded that PDXs formed 
by implanting GBM tissue fragments were similar to 
the original tumors of GBM patients [26]. In the pre-
sent study, we attempted to develop PDX models using 
tissue fragments from surgical samples of brain tumors 
using two different direct injection methods: a cut-down 
syringe and a pipette.
Methods
Patient population
Eight patients with primary brain tumors, including seven 
glioblastoma (GBM) patients and one primitive neuroe-
ctodermal tumor (PNET) patient, treated at our institu-
tion between June 2013 and October 2013, were included 
in this study (Table  1). All patients were histologically 
diagnosed and graded by neuro-pathologists according 
to 2007 World Health Organization (WHO) classification 
criteria [27]. O-6-methylguanine-DNA methyltransferase 
(MGMT) promotor methylation and isocitrate dehydro-
genase (IDH)-1 mutations were assessed by polymerase 
chain reaction (PCR) and immunohistochemistry (IHC). 
Epidermal growth factor receptor (EGFR) amplification 
and loss of heterozygosity (LOH) at chromosomes 1p 
and 19q were evaluated by fluorescent in situ hybridiza-
tion (FISH). P53 and ki-67 were examined by IHC. All 
patients provided written informed consent, and the 
study was approved by the Institutional Review Boards of 
our institution.
From fresh tumor specimen to small tissue fragments
Specimens from GBM patients were freshly obtained 
from the operating room, placed in sterile centrifuge 
tubes (SPL Life Sciences Co., Ltd, Seoul, Korea) in ice, 
and then chopped with a sterile stainless steel surgical 
blade (Paragon, Sheffield, UK) and suspended in phos-
phate-buffered saline (PBS; Mediatech, Manassas, VA, 
USA) within 30 min of being sent from the surgical room. 
Fragmented specimens, approximately 3  mm3 in size 
(Aliquots of 3 μl of suspended tumor fragments were pre-
pared for injection), were prepared for each sample [15, 
26].
Animals
Male athymic nude mice (Central Lab Animal Inc., Seoul, 
Korea), aged 4–8  weeks, were used in this study. Mice 
were housed in micro-isolator cages under sterile condi-
tions and were observed for at least 1 week before study 
initiation to ensure proper health. Lighting, temperature, 
and humidity were centrally controlled. All experimental 
procedures were approved by the Institutional Animal 
Care and Use Committee of Yonsei University College of 
Medicine.
Orthotopic xenograft of patient‑derived brain tumor tissue 
fragments
Brain tumor tissue fragments from each patient (n = 8) 
were directly injected into mice (n  =  3/group) using 
two methods: a 21 gauge, cut-down syringe (Korea Vac-
cine Co., Ltd., Gyeonggi-do, Korea), and a pipette (Gil-
son, Middleton, WI, USA) (Fig.  1). Mice were first 
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anesthetized with a solution of Zoletil (30  mg/kg; Vir-
bac Korea, Seoul, Korea) and xylazine (10  mg/kg; 
Bayer Korea, Seoul, Korea), delivered intraperitoneally. 
Then, a hole was drilled in the right side of the skull at 
the implantation position (2.5  mm lateral from sagit-
tal suture, 1  mm anterior from coronal suture) using a 
small, hand-controlled twist drill (Plastics One, Roa-
noke, VA, USA). Thereafter, patient-derived brain tumor 
tissue fragments (~3  mm3) were implanted to a depth 
of 4.5 mm in the right frontal lobe of nude mice via an 
inserted cut-down syringe or pipette.
Results
Patient-derived xenograft (PDX) models were prepared 
for eight brain tumor patients (Table  1) by implanting 
tiny tissue fragments biopsied from each patient into the 
brains of athymic mice (n = 3/group) using the two injec-
tion methods—cut-down syringe and pipette—described 
in “Methods” section. A dataset was obtained for each 
PDX that included a pathological assessment and mag-
netic resonance imaging (MRI; T1 axial enhancement) 
of the corresponding donor, the injection method, the 
lifetime of the resulting PDX, and images of hematoxylin 
Table 1 Patient characteristics
a  O(6)-methylguanine methyltransferase
b  Isocitrate dehydrogenase 1
c  Glioblastoma
d  Primitive neuroectodermal tumor
e  Non-available
f  Loss of heterozygosity
g  Epidermal growth factor receptor amplification
Age Sex WHO 
grade
Pathology MGMTa IDH1b P53 1p/19q Ki‑67 L.I. EGFRg No. 
of implanted 
mice
Case #1 24 M IV GBMc Methylation Wild type Wild type Intact 5 % 0 3
Case #2 61 M IV GBMc Unmethylation Wild type 5 % LOH/intact Focal 20–30 % and 
overall 5 %
3+ 3
Case #3 24 M IV GBMc Unmethylation Wild type 80–90 % Intact 50 % 2–3+ 3
Case #4 50 M IV GBMc Methylation Mutation NA NA NA NA 3
Case #5 62 F IV GBMc Methylation Wild type Wild type Intact 5–6 % 3+ 4
Case #6 11 M IV GBMc Unmethylation Wild type 50–60 % Intact 70–80 % 0 3
Case #7 26 M IV GBMc Unmethylation Wild type 50–60 % LOHf 40–50 % 2–3+ 3
Case #8 1.3 M IV PNETd NAe NA NA NA 50–60 % NA 3
Fig. 1 Methods for developing PDX mouse models. Athymic mice received patient‑derived surgical brain tumor tissue fragments (~3 mm3) via two 
different injection methods: 21 gauge cut‑down syringe and pipette
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and eosin (H&E)-stained histological sections of PDX 
brain tissue (Fig. 2).
The neuro-pathologists examined each PDX brain. 
Tissues were fixed in 4 % phosphate-buffered paraform-
aldehyde for 24 h, embedded in paraffin, sectioned, and 
stained with H&E to examine whether the xenografted 
tumor tissue fragments had been successfully estab-
lished. A total of 17 PDXs were prepared by injecting tis-
sue fragments via a cut-down syringe and 8 PDXs were 
prepared by injecting with a pipette. Among these PDXs, 
four in the cut-down syringe group and one in the pipette 
group died because of surgical complications. Apart from 
these dead PDXs, no PDX-bearing patient-derived brain 
tumor was detected, yielding an overall establishment 
rate of 0 %. The neuro-pathologists verified that the PDX 
brain tissue sections showed inflammation and was thus 
unlikely to be necrotic (Table 2).
Discussion
Previous studies have reported testing platforms that 
attempt to recapitulate the properties of patients’ tumors 
using tumorspheres [10] or dissociated cells [25]. One 
additional previous study also suggested that a xenograft 
formed from glioblastoma (GBM) fragments inserted 
into the brain was similar to that of the originating GBM 
tumor [26]. On the basis of these results, we hypothesized 
that brain tumor patient-derived xenograft (PDX) models 
could be successfully established through direct implan-
tation of tumor tissue fragments. To create these mod-
els, we inserted tiny tumor tissue fragments (~3  mm3), 
biopsied from brain tumor patients, into the brains of 
athymic mice using two injection methods: a cut-down 
syringe and a pipette. Among these PDXs, ~3 % died due 
to surgical complication. Inflammation was the only fatal 
surgical complication observed, and mice subject to it 
died an average of 5 days post-op. The post-op survival of 
all other mice was longer than 6 months. An analysis of 
each PDX brain tissue section to determine whether the 
xenografted tumor tissue fragments successfully became 
established unexpectedly revealed a tumor-establishment 
rate for xenografted brain tumor tissue fragments of 0 %. 
Thus, contrary to our hypothesis, we could not develop 
brain tumor PDXs from tumor tissue fragments, consid-
ered an ideal method for immortalization of a patient’s 
cancer.
Considerable effort has been devoted to identify-
ing potential animal hosts for xenotransplantation of 
human cells for use in the development of animal mod-
els for human diseases. As a consequence, a number 
of immunocompromised mouse models, including 
athymic nude mice and severe combined immunodefi-
cient (SCID) mice, have been developed. Motivated by 
Fig. 2 Example of a PDX data set. Each data set included the pathology of the donor patient, an MRI (T1 axial enhancement) image of the donor 
patient, PDX number, injection method, lifetime of the PDX, and an H&E‑stained histological section of PDX brain tissue. This data set corresponds 
to that for tumor tissue fragments from a glioblastoma patient with a T1 contrast‑enhanced lesion in the right temporoparietal lobe implanted into 
PDX mouse #22 through a pipette. No xenograft patient‑derived tumor tissue fragments were detected in H&E‑stained histological sections of brain 
tissue from this mouse, as confirmed by Neuro‑pathologists
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previous research [26], we used T cell deficient athymic 
nude mice as xenografts animal subjects. However, these 
mice still have functional B cells, which could cause fail-
ure of engraftment. Accordingly, a change in animal 
model to SCID mice, which are defective in functional T 
and B cell, could facilitate engraftment. One report has 
also suggested NOD/SCID/γcnull mice, a modified SCID 
mouse with multiple immunological dysfunctions, as an 
animal recipient for improving the engraftment success 
of xenografts [28].
From the standpoint of transplanting tumors most like 
the original, our study is similar to a previous report [26]. 
Fei et  al. injected 2  mm3 of tumor tissue fragments per 
mouse in a total maximum volume of 20 μl injected cell 
suspension [26, 29, 30]. Here, we implanted 3  mm3 of 
suspended tumor tissue fragments per mouse, in an effort 
to increase the amount of tissue fragments implanted. In 
both studies, the tumor tissue fragments were injected 
into mice within 5  min (from anesthesia to closure of 
skull hole). In our study, it took about 15 min to transfer 
the samples from the operating room to the laboratory, 
and 15 min to chop the samples, but no specific sample 
movement time was reported in the previous study. We 
used a cut-down syringe and pipette to insert tumor tis-
sue fragments, whereas the previous study used a trocar 
for injection. This single known difference in methodol-
ogy may have caused differences in the total volume of 
injected tissue fragments, resulting in the implantation 
of a relatively small number tumor cells in our study. It 
might also have produced differences in injection pres-
sure or speed that ultimately proved detrimental.
In this study, no PDX-bearing patient-derived brain 
tumor was detected. It is possible that this might reflect a 
loss of cell viability, perhaps due to our brief placement of 
fresh patient-derived brain tumor tissue fragments in ice, 
or the suspension of brain tumor tissue fragments in PBS 
(which was required because otherwise the chopped tis-
sue fragments were too sticky). We do not believe, how-
ever, that there was any issue with loss of cell viability. We 
used PBS instead of medium to exclude any effects from 
factors found in the medium. Specimens were chopped 
with a surgical blade and suspended in PBS within 
30 min being sent from the surgical room, and were then 
injected within 30  min of the chopping step. Moreover, 
we performed cell culture using specimens placed in ice 
and suspended with PBS, as described in our protocol, 
and successfully obtained cultured tumor cells (Addi-
tional file 1: Figure S1). Additional method for cell isola-
tion was described in Additional file 2. Finally, previous 
reports have described the successful isolation of viable 
cells using the same method [23, 24]. Thus, we believe 
that our patient-derived brain tumor tissue fragments 
maintained their viability during the processing steps.
The 0  % tumor-establishment rate for xenografted 
brain tumor tissue fragments may be attributable to these 
differences. However, despite the differences between our 
method and the trocar injection system, the basic con-
cept of both methods is similar. Thus, notwithstanding 
a previous report of GBM PDX models prepared using 
athymic mice, our results suggest that tissue fragments 
of surgical brain tumor specimens from patients may be 
unsuitable for implementation of brain tumor PDX mod-
els. Previous reports described the successful develop-
ment of brain tumor xenograft models using the same 
methods applied in the present work [23, 24, 31]. Though 
the methods in this study were proved through previous 
reports, alteration of some method conditions such as 
alternative tissue preparation, injection techniques, and 
selection of immunodeficient animals can prove more 
successful in establishing brain tumor PDX models.
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